 Zacks Investment Research upgraded shares of Aridis Pharmaceuticals NASDAQ:ARDS from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The ... 